NIH RePORTER
Cure8 research brief
Why This Matters
Pouchitis affects a large share of patients after IPAA surgery and causes significant morbidity. Identifying pre-surgery immune, epithelial, or microbial signatures that predict pouchitis could help guide who should get an IPAA or suggest preventive treatments.
Who Should Pay Attention
Researchers studying IBD pathogenesis, clinicians managing patients being considered for IPAA surgery, and patients considering or living with an ileal pouch.
Study Snapshot
Story typeCompany update
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
This is a funded NIH project record from NYU investigating predictors and mechanisms of pouchitis after restorative proctocolectomy with IPAA.
The team will use multi-modal single-cell approaches (ExCITE-seq), spatial transcriptomics, organoid models, and metagenomic stool analyses from pre-IPAA ileal tissue and ileostomy stool to link pre-surgery immune-epithelial and microbial features to later development of pouchitis.
The goal is to identify predictive immune, epithelial, and microbial biomarkers that could inform IPAA eligibility and preventive strategies. The project appears to be a prospective, mechanistic research program rather than a clinical trial of a specific drug.
Methods described include single-cell and spatial transcriptomics, organoid experiments testing effects of Th17-associated cytokines on epithelial fate/viability, and integrated metagenomic analyses of stool.
The record frames pouchitis as a common post-IPAA complication and focuses on Th17-driven immune dysregulation, epithelial remodeling, clonal T cell expansion, epigenetic changes in stem cells, and microbiome interactions.
This brief summarizes the project abstract provided on the NIH Reporter page and does not represent a review of any full study data or peer-reviewed publication.
Keep In Mind
This entry is a funded research project record (NIH Reporter) describing planned and ongoing studies; it does not report completed trial results. Findings will require peer-reviewed publication and clinical validation before changing care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsJordan Eric Axelrad
InstitutionNEW YORK UNIVERSITY SCHOOL OF MEDICINE
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedJul 14, 2026, 12:00 AM
Content availableResearch project record
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases - R01DK147073 - $845,994
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
INTERROGATING GCPII-MEDIATED GLUTAMATE SIGNALING IN THE GASTROINTESTINAL TRACT AND ITS ROLE IN INTESTINAL HOMEOSTASIS
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
From signals to systems: the epigenetic-microbiome-mitochondrial axis in IBD pathogenesis.
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...